Fortress Biotech, Inc. (FBIO)
NASDAQ: FBIO · Real-Time Price · USD
1.930
-0.040 (-2.03%)
At close: Jul 23, 2025, 4:00 PM
1.930
0.00 (0.00%)
After-hours: Jul 23, 2025, 4:36 PM EDT

Company Description

Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products.

The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-nodular moderate to severe acne vulgaris; Zilxi for inflammatory lesions of rosacea; Exelderm, an antifungal cream and solution for topical use; Targadox, an oral doxycycline drug for therapy for severe acne; and Luxamend, a water-based emulsion to provide a moist healing environment for superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, sunburns, and radiation dermatitis.

It also develops intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for Menkes disease; UNLOXCYT for metastatic cutaneous squamous cell carcinoma; Olafertinib for EGFR mutation-positive NSCLC; CAEL-101, a monoclonal antibody for amyloid light chain amyloidosis; and Triplex, a cytomegalovirus vaccine.

In addition, the company’s early-stage product candidates include Dotinurad for gout; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma and anaplastic astrocytoma; MB-106 for B-cell non-hodgkin lymphoma; AJ201, an androgen receptor degradation enhancer; and BAER-101, a positive allosteric modulator.

Further, its preclinical product candidates comprise AAV-ATP7A and AVTS-001 gene therapies; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform.

The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015.

Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Fortress Biotech, Inc.
Fortress Biotech logo
CountryUnited States
Founded2006
IndustryBiotechnology
SectorHealthcare
Employees101
CEOLindsay Rosenwald

Contact Details

Address:
1111 Kane Concourse, Suite 301
Bay Harbor Islands, Florida 33154
United States
Phone781 652 4500
Websitefortressbiotech.com

Stock Details

Ticker SymbolFBIO
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001429260
CUSIP Number34960Q109
ISIN NumberUS34960Q3074
Employer ID20-5157386
SIC Code2834

Key Executives

NamePosition
Dr. Lindsay Allan Rosenwald M.D.Executive Chairman, President and Chief Executive Officer
David JinChief Financial Officer and Head of Corporate Development
Dr. Xiaoqin Lu M.D.Chief Strategy Officer
Michael S. Weiss Esq., J.D.Executive Vice Chairman of Strategic Development and Director
Samuel BerryGeneral Counsel and Corporate Secretary
Dr. George C. Avgerinos Ph.D.Senior Vice President of Biologics Operations

Latest SEC Filings

DateTypeTitle
Jul 16, 20258-KCurrent Report
Jun 23, 20258-KCurrent Report
Jun 5, 20258-KCurrent Report
Jun 3, 20254Statement of changes in beneficial ownership of securities
May 15, 202510-QQuarterly Report
May 15, 20258-KCurrent Report
Apr 28, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 28, 2025DEF 14AOther definitive proxy statements
Apr 18, 2025PRE 14AOther preliminary proxy statements
Apr 16, 20258-KCurrent Report